This is a Validated Antibody Database (VAD) review about human MAP3K2, based on 3 published articles (read how Labome selects the articles), using MAP3K2 antibody in all methods. It is aimed to help Labome visitors find the most suited MAP3K2 antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
MAP3K2 synonym: MEKK2; MEKK2B; mitogen-activated protein kinase kinase kinase 2; MAP/ERK kinase kinase 2; MAPK/ERK kinase kinase 2; MEK kinase 2; MEKK 2

Knockout validation
Abcam
rabbit monoclonal (EP626Y)
  • western blot knockout validation; mouse; loading ...; fig 2a
Abcam MAP3K2 antibody (Abcam, ab33918) was used in western blot knockout validation on mouse samples (fig 2a). Oncogene (2018) ncbi
Abcam
rabbit monoclonal (EP626Y)
  • western blot knockout validation; mouse; loading ...; fig 2a
Abcam MAP3K2 antibody (Abcam, ab33918) was used in western blot knockout validation on mouse samples (fig 2a). Oncogene (2018) ncbi
rabbit monoclonal (EP626Y)
  • western blot; human; fig 3e
In order to study the role of statin and ERK5 in tight junction formation and function in endothelial cells, Abcam MAP3K2 antibody (Abcam, ab33918) was used in western blot on human samples (fig 3e). J Cell Physiol (2018) ncbi
rabbit monoclonal (EP626Y)
  • western blot; human; loading ...; fig 5b
Abcam MAP3K2 antibody (Abcam, ab33918) was used in western blot on human samples (fig 5b). Int J Oncol (2016) ncbi
Articles Reviewed
  1. Lu J, Liu L, Zheng M, Li X, Wu A, Wu Q, et al. MEKK2 and MEKK3 suppress Hedgehog pathway-dependent medulloblastoma by inhibiting GLI1 function. Oncogene. 2018;37:3864-3878 pubmed publisher
  2. Wilkinson E, Sidaway J, Cross M. Statin regulated ERK5 stimulates tight junction formation and reduces permeability in human cardiac endothelial cells. J Cell Physiol. 2018;233:186-200 pubmed publisher
  3. Huang T, She K, Peng G, Wang W, Huang J, Li J, et al. MicroRNA-186 suppresses cell proliferation and metastasis through targeting MAP3K2 in non-small cell lung cancer. Int J Oncol. 2016;49:1437-44 pubmed publisher